Did our AI summary help? A research-level mathematics problem that took nearly twenty years to design has been solved by an artificial intelligence system, surprising the mathematician who created it.

You’re never too old to learn something new. People are losing their minds over how simple — yet tricky — an elementary school-level math equation posted on X (formerly Twitter) is. Over the weekend, ...

Add Futurism (opens in a new tab) Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. Artificial intelligence ...

AppControl is a modern Task Manager alternative designed to give users deeper visibility and control over system activity. In this post, we will show you how to track, control, and monitor a Windows ...

During the pandemic, Rishik Shenolikar offered to help tutor neighborhood kids in his garage. It was a small group of elementary schoolers, and he used a mental math book that intrigued him. He helped ...

Gamers have been praising the long lifespan of their Nintendo Switch Pro Controllers. While Nintendo doesn't offer any expectations for its Pro Controllers' lifespans, it seems like plenty of users ...

A new software update for Analogue’s modern recreation of the N64 makes authentic retro gaming more convenient. A new software update for Analogue’s modern recreation of the N64 makes authentic ...

The M4’s magnetic mount securely sticks to your phone but sometimes struggles to stay attached to the actual controller. The M4’s magnetic mount securely sticks to your phone but sometimes struggles ...

Per the terms of the agreement, Novavax will receive an upfront payment of $30 million from Pfizer and is eligible to earn up to $500 million in potential development and commercial milestone payments ...

Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments. The biotech company said ...